SDC1 and melanoma: Moreover, we observed that in human melanoma xenograft, targeting SDC1 via scFv OC-46F2 enhanced the therapeutic efficacy of L19-IL2, an immunocytokine composed of an scFv specific for the angiogenesis-associated B-fibronectin isoform and IL2, inhibiting tumor growth and VM processes [25].